Ametris - formerly ActiGraph

02/20/2026

The Sleep and Scratch session at ADDS 2026 addresses objectively measuring the "sleep & scratch cycle." Traditional subjective recalls often miss the true burden of nocturnal scratching and its impact on sleep quality.

This session features experts from Ametris, Matthew Patterson and Andy Liu, and Johnson & Johnson Innovative Medicine's Mark Morris discussing the latest in wearable and touchless DHTs. Highlights include the DECODE Nocturnal Scratch initiative and new data on identifying Total Sleep Opportunity to better differentiate between sleep and immobility.

Join us to learn more on how medical-grade wearables are providing the objective evidence needed to accelerate dermatology and sleep research: https://hubs.la/Q043XcNx0

02/17/2026

Ametris will be at ISCTM in D.C., discussing how high-fidelity wearables replace subjective recall bias with objective, 24/7 digital evidence.

Connect with Jon Lake in advance to see how we’re accelerating timelines.


📅 Let's talk: https://hubs.la/Q043s6jz0

02/17/2026

At the 2026 SCOPE Summit, Ametris CEO Jeremy Wyatt was interviewed by Andy Studna from Applied Clinical Trials on operational best practices for integrating wearables into oncology trials to minimize patient burden, support proper device selection and workflow design, and ensure digital measures fit the realities of complex patient populations across regulatory landscapes.

“Digital measures enable continuous engagement with patients while often reducing clinic visits and overall burden. In some cases, we’ve even seen reductions in required sample size due to the statistical power of these measures.”

Find Part 2 of Jeremy’s video interview at the link below in the comments: https://hubs.ly/Q043pxgX0

02/16/2026

There’s just 1 week remaining until ADDS 2026, held in Atlanta from February 23- 25. This premier scientific conference dedicated to multidisciplinary research deep dives into the practical application of wearable Digital Health Technologies (DHTs) with clinical research.

A key highlight of this year's program is our Pharma Innovation Showcase, where industry leaders will share first-hand insights on scaling digital solutions with global, industry-leading organizations:
🔹 Digital Health Innovation Hub: Driving Integration of DHTs in Clinical Development | Presented by Brian Winger, PhD from Eli Lilly and Company
🔹 Accelerating Digital Health Innovation with China for Global Clinical Development | Presented by Yue Wang, PhD from AstraZeneca China
🔹 Wearable Innovation in Heart Failure: Toward Closing Unmet Needs | Presented by Elias Abou Zeid, PhD from Novo Nordisk

02/13/2026

Traditional clinical outcome measures are often inadequate for assessing drug efficacy in neuromuscular disorder (NMD) trials, making the development of novel treatments a challenge in an area where there is a large unmet need for new therapy options. Wearable digital health technologies (DHTs) provide an unprecedented opportunity to directly and objectively assess real-world function throughout all stages of disease progression to accelerate drug development in NMDs.

As an experienced digital evidence generation partner, sour expertise spans research across key neuromuscular diseases such as Parkinson's Disease (PD), Huntington’s Disease (HD), and Duchenne Muscular Dystrophy (DMD) by providing high-fidelity data that captures the patient’s real-world function and behavior.

Our specialized solutions include comprehensive cardinal symptom monitoring for PD and HD—specifically tracking bradykinesia, dyskinesia, and tremor—alongside our newly integrated functional capacity measures.

We’ve expanded our toolkit to include Stride Velocity 95th Centile (SV95C)and the novel Six-Minute Activity 95th Centile (6M95C), objective digital measures of functional capacity that enable the tracking of progression and treatment effect in both ambulatory and non-ambulatory stages of disease—

Visit our new NMD therapeutic expertise page to learn how Ametris is transforming clinical research in this challenging therapeutic area: https://hubs.la/Q0434w8H0

02/12/2026

As R&D in obesity and related metabolic disorders continues to accelerate with the rise of GLP-1 treatments, the need for evidence on health benefits beyond weight loss will be critical to optimize program success, differentiate treatments, and support payer negotiations. Wearable DHT can capture continuous, real-world mobility, physical activity, sleep, and vital sign measures with minimal burden, and are crucial to support the next generation of novel treatments.

To address this evidence gap and advance novel treatments, Ametris has joined forces with industry leaders Eli Lilly, Roche, Novo Nordisk, and AstraZeneca to launch DECODE-Obesity. This collaborative initiative aims to strengthen the evidentiary foundation for obesity treatments by focusing on three key areas - generating evidence on clinically meaningful outcome measures, assessing patient perspectives on disease impact and DHT usability, and engaging with regulators to gain support and streamline approval requirements.

To learn more about how Ametris is advancing clinical development in Obesity and Metabolic Disorders, visit our new Therapeutic Expertise page: https://hubs.la/Q042HjL60

02/11/2026

Last week, at the 2026 SCOPE Summit, Ametris CEO Jeremy Wyatt was interviewed by Andy Studna from Applied Clinical Trials on operational best practices for integrating wearables into oncology trials to minimize patient burden, support proper device selection and workflow design, and ensure digital measures fit the realities of complex patient populations.

“Device selection is key. If we’re going to collect digital measures in oncology—or any patient population—we need to choose products that are patient-friendly, low burden, easy to use, and fit for the endpoint we’re trying to measure. Data quality also has to be considered early. How do we handle missing data? How do we clean it? How do we integrate it with the broader evidence package so it’s ready when needed?”

Find Part 1 of Jeremy’s video interview here:

Jeremy Wyatt, CEO, Ametris, discusses how operational best practices for integrating wearables into oncology trials center on minimizing patient burden through thoughtful workflow design, careful device selection, and early planning to ensure digital measures fit the realities of complex patient pop...

02/10/2026

The Ametris Digital Data Summit 2026 is just two weeks away! Join us in Atlanta (February 23-25) in Atlanta to connect with 50+ attendees and industry leaders to advance the adoption of wearable DHTs in clinical research.

3 Days. 50+ Experts & attendees. Exclusive networking to key biopharma leaders.

Expert contributors include:
🔹Michelle Campbell, Associate Director, Stakeholder Engagement and Clinical Outcomes, Office of Neuroscience at the FDA
🔹Carrie Northcott, Head of Digital Medicine and Translational Imaging
🔹Lori Quinn, Professor at Columbia University
🔹Jonas Dorn, Digital Biomarker Tech Lead at Roche
🔹Brian Winger, Associate VP, Digital Health, Portfolio Owner and Device Engineering Leader at Eli Lilly

Register today: https://hubs.la/Q042wzFy0

02/09/2026

We're looking forward to connecting with the researchers and industry leaders at the International Society for CNS Clinical Trials & Methodology (ISCTM) Annual Scientific Meeting to discuss the evolving landscape of CNS drug development.

Attending the conference? Connect with one of our Ametris team, Jon Lake. Whether you’re interested in the latest in digital health tech or looking to optimize your next study’s methodology, we'd love to talk.

📅 Schedule a meeting with us! https://hubs.la/Q042hxBB0

02/06/2026

Disrupted sleep patterns and quality are characteristic of sleep disorders and impact other areas of patient well-being, including their physical functioning. Wearable DHTs can detect unique functional changes associated with sleep disorders and treatment interventions, providing quantifiable measures of participant behavior that is otherwise difficult to obtain.

Visit our new resource page to explore how DHT can help unlock meaningful insights across a variety of sleep disorders, including narcolepsy, idiopathic hypersonic, and insomnia.

Explore our expertise and solutions for sleep disorder research
🔗 https://hubs.la/Q0423S8Y0

02/05/2026

In a recent study published in Pediatric Neurology, researchers introduce 6M95C, a novel accelerometry-based digital measure designed to complement the regulatory-qualified SV95C by capturing functional capacity across all disease stages in patients with DMD.

During last week's webinar, several of the study authors, including Jonathon Soslow, MD MSCI of Vanderbilt University Medical Center and Ametris scientists Rakesh Pilkar and Andrew Liu, discussed the development, validation, and clinical implications of 6M95C in DMD research.

In case you missed it, watch the on-demand recording of last week’s webinar at the link in the comments below.

02/04/2026

We’re excited to highlight the abstracts and presenters selected for the ADDS 2026 Scientific Poster Session. This interactive research showcase offers attendees and presenters the opportunity to connect, explore emerging findings, and discuss how we can continue moving the field forward.

We invite you to see the groundbreaking research firsthand at ADDS 2026, February 23-25 in Atlanta by registering today.

To bring your team, take advantage of our special group pricing discount where you can buy 3 tickets and get the 4th for free!
https://hubs.la/Q041ThdR0